Nationwide retrospective mortality and seroprevalence of SARS-CoV-2 antibodies in Cameroon
Background: Although the first year of the COVID-19 pandemic in Africa did not produce the expected catastrophe, the true impact of COVID-19 in the Cameroonian population was unclear. We therefore assessed the seroprevalence of anti-SARS-CoV-2 antibodies and retrospective mortality in a representati...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-11-01
|
| Series: | Scientific African |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2468227623003800 |
| _version_ | 1797429657471025152 |
|---|---|
| author | J. Eyong K.N. Fai B. Nikolay E. Gignoux R. Nsaibirni D. Buri F. Yuya E. Youm R. Ntone N.F. Mbarga L. Matchim D. Tchiasso A. Ngosso E. Nanda C. Yonta M. Ndifon R.G. Essomba F. Wanda N. Mandeng R. Essaka M.T. Koku S. Eyangoh M. Ousman L. Esso E. Epée R. Njouom M.C.A. Okomo I. Ciglenecki G.A. Mballa S. Issoufou K. Porten Y. Boum |
| author_facet | J. Eyong K.N. Fai B. Nikolay E. Gignoux R. Nsaibirni D. Buri F. Yuya E. Youm R. Ntone N.F. Mbarga L. Matchim D. Tchiasso A. Ngosso E. Nanda C. Yonta M. Ndifon R.G. Essomba F. Wanda N. Mandeng R. Essaka M.T. Koku S. Eyangoh M. Ousman L. Esso E. Epée R. Njouom M.C.A. Okomo I. Ciglenecki G.A. Mballa S. Issoufou K. Porten Y. Boum |
| author_sort | J. Eyong |
| collection | DOAJ |
| description | Background: Although the first year of the COVID-19 pandemic in Africa did not produce the expected catastrophe, the true impact of COVID-19 in the Cameroonian population was unclear. We therefore assessed the seroprevalence of anti-SARS-CoV-2 antibodies and retrospective mortality in a representative sample of the general population in the 10 administrative regions of Cameroon more than one year after the first confirmed cases of COVID-19 in these regions. We aimed to assess the extent of SARS-COV-2 infection and to detect potential increases in the crude mortality rate (CMR) during the SARS-COV-2 pandemic phase. Methods: We assessed retrospective mortality and seroprevalence of anti-SARS-CoV-2 antibodies in the 10 capital cities of Cameroon using representative samples of the general population. The study included nested anti-SARS-CoV-2 antibody prevalence surveys and retrospective mortality surveys and was conducted between 27 July 2021 and 31 August 2021. To further analyze crude mortality rates by age group and COVID wave, pre-pandemic and pandemic periods were stratified. Both laboratory-based assays (ELFA) and rapid diagnostic tests (RDT) were used to measure anti-SARS-CoV-2 seroprevalence. Results: The crude mortality rate (CMR) increased from 0.06 deaths per 10 000 persons per day (pre-pandemic) to 0.17 deaths per 10 000 persons per day (pandemic). The increase in CMR was more pronounced in people aged 20–35 years (pre-pandemic 0.02 deaths per 10 000 persons per day; pandemic 0.06 deaths per 10 000 persons per day). The estimated seroprevalence among unvaccinated persons was 9.5 % (RDT) and 15.4 % (laboratory-based). Conclusion: The seroprevalence results showed that cases were significantly underdetected by the national surveillance systems. |
| first_indexed | 2024-03-09T09:16:19Z |
| format | Article |
| id | doaj.art-e570de930374424f9b772e10b336052d |
| institution | Directory Open Access Journal |
| issn | 2468-2276 |
| language | English |
| last_indexed | 2024-03-09T09:16:19Z |
| publishDate | 2023-11-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Scientific African |
| spelling | doaj.art-e570de930374424f9b772e10b336052d2023-12-02T07:06:21ZengElsevierScientific African2468-22762023-11-0122e01925Nationwide retrospective mortality and seroprevalence of SARS-CoV-2 antibodies in CameroonJ. Eyong0K.N. Fai1B. Nikolay2E. Gignoux3R. Nsaibirni4D. Buri5F. Yuya6E. Youm7R. Ntone8N.F. Mbarga9L. Matchim10D. Tchiasso11A. Ngosso12E. Nanda13C. Yonta14M. Ndifon15R.G. Essomba16F. Wanda17N. Mandeng18R. Essaka19M.T. Koku20S. Eyangoh21M. Ousman22L. Esso23E. Epée24R. Njouom25M.C.A. Okomo26I. Ciglenecki27G.A. Mballa28S. Issoufou29K. Porten30Y. Boum31Epicentre, Yaoundé, Cameroon; Corresponding author at: Epicentre, Bastos, BP 12069, Yaoundé, Cameroun.Epicentre, Yaoundé, CameroonEpicentre, Paris, FranceEpicentre, Paris, FranceEpicentre, Yaoundé, CameroonEpicentre, Yaoundé, CameroonEpicentre, Yaoundé, CameroonEpicentre, Yaoundé, CameroonEpicentre, Yaoundé, CameroonMédecins Sans Frontières OCG, Yaoundé, CameroonEpicentre, Yaoundé, CameroonEpicentre, Yaoundé, CameroonEpicentre, Yaoundé, CameroonEpicentre, Yaoundé, CameroonEpicentre, Yaoundé, CameroonEpicentre, Yaoundé, CameroonNational Public Health Laboratory, Yaoundé, Cameroon; Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, CameroonCIRES, Akonolinga, CameroonPublic Health Emergencies Operation Coordination Center, Ministry of Health, Yaoundé, CameroonLaboratoire du Lac, Yaoundé, CameroonMédecins Sans Frontières OCG, Yaoundé, CameroonCentre Pasteur du Cameroun, Yaoundé, CameroonLaboratoire du Lac, Yaoundé, CameroonFaculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Cameroon; Public Health Emergencies Operation Coordination Center, Ministry of Health, Yaoundé, CameroonPublic Health Emergencies Operation Coordination Center, Ministry of Health, Yaoundé, CameroonCentre Pasteur du Cameroun, Yaoundé, CameroonNational Public Health Laboratory, Yaoundé, Cameroon; Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, CameroonMédecins Sans Frontières OCG, Geneva, SwitzerlandPublic Health Emergencies Operation Coordination Center, Ministry of Health, Yaoundé, CameroonMédecins Sans Frontières WaCA, Abidjan, Côte d'IvoireEpicentre, Paris, FranceEpicentre, Yaoundé, Cameroon; Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Cameroon; Public Health Emergencies Operation Coordination Center, Ministry of Health, Yaoundé, CameroonBackground: Although the first year of the COVID-19 pandemic in Africa did not produce the expected catastrophe, the true impact of COVID-19 in the Cameroonian population was unclear. We therefore assessed the seroprevalence of anti-SARS-CoV-2 antibodies and retrospective mortality in a representative sample of the general population in the 10 administrative regions of Cameroon more than one year after the first confirmed cases of COVID-19 in these regions. We aimed to assess the extent of SARS-COV-2 infection and to detect potential increases in the crude mortality rate (CMR) during the SARS-COV-2 pandemic phase. Methods: We assessed retrospective mortality and seroprevalence of anti-SARS-CoV-2 antibodies in the 10 capital cities of Cameroon using representative samples of the general population. The study included nested anti-SARS-CoV-2 antibody prevalence surveys and retrospective mortality surveys and was conducted between 27 July 2021 and 31 August 2021. To further analyze crude mortality rates by age group and COVID wave, pre-pandemic and pandemic periods were stratified. Both laboratory-based assays (ELFA) and rapid diagnostic tests (RDT) were used to measure anti-SARS-CoV-2 seroprevalence. Results: The crude mortality rate (CMR) increased from 0.06 deaths per 10 000 persons per day (pre-pandemic) to 0.17 deaths per 10 000 persons per day (pandemic). The increase in CMR was more pronounced in people aged 20–35 years (pre-pandemic 0.02 deaths per 10 000 persons per day; pandemic 0.06 deaths per 10 000 persons per day). The estimated seroprevalence among unvaccinated persons was 9.5 % (RDT) and 15.4 % (laboratory-based). Conclusion: The seroprevalence results showed that cases were significantly underdetected by the national surveillance systems.http://www.sciencedirect.com/science/article/pii/S2468227623003800MortalitySeroprevalenceSARS-CoV-2Cameroon |
| spellingShingle | J. Eyong K.N. Fai B. Nikolay E. Gignoux R. Nsaibirni D. Buri F. Yuya E. Youm R. Ntone N.F. Mbarga L. Matchim D. Tchiasso A. Ngosso E. Nanda C. Yonta M. Ndifon R.G. Essomba F. Wanda N. Mandeng R. Essaka M.T. Koku S. Eyangoh M. Ousman L. Esso E. Epée R. Njouom M.C.A. Okomo I. Ciglenecki G.A. Mballa S. Issoufou K. Porten Y. Boum Nationwide retrospective mortality and seroprevalence of SARS-CoV-2 antibodies in Cameroon Scientific African Mortality Seroprevalence SARS-CoV-2 Cameroon |
| title | Nationwide retrospective mortality and seroprevalence of SARS-CoV-2 antibodies in Cameroon |
| title_full | Nationwide retrospective mortality and seroprevalence of SARS-CoV-2 antibodies in Cameroon |
| title_fullStr | Nationwide retrospective mortality and seroprevalence of SARS-CoV-2 antibodies in Cameroon |
| title_full_unstemmed | Nationwide retrospective mortality and seroprevalence of SARS-CoV-2 antibodies in Cameroon |
| title_short | Nationwide retrospective mortality and seroprevalence of SARS-CoV-2 antibodies in Cameroon |
| title_sort | nationwide retrospective mortality and seroprevalence of sars cov 2 antibodies in cameroon |
| topic | Mortality Seroprevalence SARS-CoV-2 Cameroon |
| url | http://www.sciencedirect.com/science/article/pii/S2468227623003800 |
| work_keys_str_mv | AT jeyong nationwideretrospectivemortalityandseroprevalenceofsarscov2antibodiesincameroon AT knfai nationwideretrospectivemortalityandseroprevalenceofsarscov2antibodiesincameroon AT bnikolay nationwideretrospectivemortalityandseroprevalenceofsarscov2antibodiesincameroon AT egignoux nationwideretrospectivemortalityandseroprevalenceofsarscov2antibodiesincameroon AT rnsaibirni nationwideretrospectivemortalityandseroprevalenceofsarscov2antibodiesincameroon AT dburi nationwideretrospectivemortalityandseroprevalenceofsarscov2antibodiesincameroon AT fyuya nationwideretrospectivemortalityandseroprevalenceofsarscov2antibodiesincameroon AT eyoum nationwideretrospectivemortalityandseroprevalenceofsarscov2antibodiesincameroon AT rntone nationwideretrospectivemortalityandseroprevalenceofsarscov2antibodiesincameroon AT nfmbarga nationwideretrospectivemortalityandseroprevalenceofsarscov2antibodiesincameroon AT lmatchim nationwideretrospectivemortalityandseroprevalenceofsarscov2antibodiesincameroon AT dtchiasso nationwideretrospectivemortalityandseroprevalenceofsarscov2antibodiesincameroon AT angosso nationwideretrospectivemortalityandseroprevalenceofsarscov2antibodiesincameroon AT enanda nationwideretrospectivemortalityandseroprevalenceofsarscov2antibodiesincameroon AT cyonta nationwideretrospectivemortalityandseroprevalenceofsarscov2antibodiesincameroon AT mndifon nationwideretrospectivemortalityandseroprevalenceofsarscov2antibodiesincameroon AT rgessomba nationwideretrospectivemortalityandseroprevalenceofsarscov2antibodiesincameroon AT fwanda nationwideretrospectivemortalityandseroprevalenceofsarscov2antibodiesincameroon AT nmandeng nationwideretrospectivemortalityandseroprevalenceofsarscov2antibodiesincameroon AT ressaka nationwideretrospectivemortalityandseroprevalenceofsarscov2antibodiesincameroon AT mtkoku nationwideretrospectivemortalityandseroprevalenceofsarscov2antibodiesincameroon AT seyangoh nationwideretrospectivemortalityandseroprevalenceofsarscov2antibodiesincameroon AT mousman nationwideretrospectivemortalityandseroprevalenceofsarscov2antibodiesincameroon AT lesso nationwideretrospectivemortalityandseroprevalenceofsarscov2antibodiesincameroon AT eepee nationwideretrospectivemortalityandseroprevalenceofsarscov2antibodiesincameroon AT rnjouom nationwideretrospectivemortalityandseroprevalenceofsarscov2antibodiesincameroon AT mcaokomo nationwideretrospectivemortalityandseroprevalenceofsarscov2antibodiesincameroon AT iciglenecki nationwideretrospectivemortalityandseroprevalenceofsarscov2antibodiesincameroon AT gamballa nationwideretrospectivemortalityandseroprevalenceofsarscov2antibodiesincameroon AT sissoufou nationwideretrospectivemortalityandseroprevalenceofsarscov2antibodiesincameroon AT kporten nationwideretrospectivemortalityandseroprevalenceofsarscov2antibodiesincameroon AT yboum nationwideretrospectivemortalityandseroprevalenceofsarscov2antibodiesincameroon |